EquityBulls

Latest News

Keywords Selected: ZydusLifesciences

Stock Report

Zydus receives final approval from USFDA for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
Zydus receives final approval from USFDA for Prucalopride Tablets, 1 mg and 2 mg
Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 & 1 mg
Zydus announces completion of the acquisition of an 85.6% stake in Amplitude Surgical
Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg
Closure of Remote Regulatory Assessment by the USFDA at Matoda, Gujarat facility
Zydus receives final approval from USFDA for Celecoxib Capsules, 50 mg, 100 mg, 200 mg and 400 mg
Closure of USFDA inspection at Zydus' oncology injectable plant at Ahmedabad
Zydus receives EIR for the API manufacturing facility at Ankleshwar
Zydus receives EIR for the API manufacturing facility at Dabhasa
Zydus enters global biologics CDMO business, plans to acquire Agenus’ U.S. manufacturing facilities to accelerate development of innovative therapies
Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
Zydus receives final approval from USFDA for Isotretinoin Capsules USP, 10 mg 20 mg, 25 mg, 30 mg, 35 mg and 40 mg
Zydus receives EIR for the Ambernath API manufacturing facility
Zydus Lifesciences completes 25 years of listing on NSE, commemorated with a bell ringing ceremony at NSE
Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg
Closure of USFDA inspection at Zydus' API Unit at Dabhasa, Gujarat
Zydus Lifesciences Limited signs purchase agreement with PAI Partners and other shareholders to acquire a majority stake in Amplitude Surgical SA
Zydus Medtech and Braile Biomedica of Brazil announce global licensing pact to commercialise TAVI technology
Zydus Lifesciences Ltd announces the execution of undertakings to tender as part of its envisaged tender offer for Amplitude Surgical SA shares
Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery
Zydus receives final approval from USFDA for Jaythari (Deflazacort) Tablets, 6 mg, 18 mg, 30 mg, and 36 mg
Zydus receives final approval from USFDA for Apalutamide Tablets, 60 mg
Zydus receives final approval from USFDA for Eluxadoline Tablets, 75 mg and 100 mg